Affymax's Share Price Stumbles On Questionable Phase III Hematide Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.